Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Puneeth Iyengar, MD, PhD, assistant professor of Radiation Oncology at UT Southwestern Medical Center, discusses the use of a hypofractionated course of radiation therapy for patients with stage 3 NSCLC.
The current standard therapy for stage 3 NSCLC is a combination of chemotherapy and radiation. Some patients are unable to tolerate chemotherapy for a variety of reasons and receive 6 weeks of radiation therapy instead. Iyengar's study compared that conventional schedule with a hypofractionated course, for just 3 weeks.